New combo shows promise for aggressive breast cancer
NCT ID NCT02689427
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a combination of enzalutamide (a hormone blocker) and paclitaxel (chemotherapy) given before surgery to 24 people with a specific type of triple-negative breast cancer that has androgen receptors. The goal was to see if this treatment could shrink tumors and reduce the amount of tissue needing removal. The trial is complete, and results will help guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Enzalutamide and paclitaxel
- What this could lead to
- If successful, this combination could offer a new treatment option for a hard-to-treat breast cancer type, potentially shrinking tumors before surgery and improving outcomes.
- What could go wrong
- This is a small, early-phase study with only 24 participants. Results may not apply to all patients, and side effects from chemotherapy and hormone therapy are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
MD Anderson West Houston
Houston, Texas, 77079, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Fasting during chemo: a new way to boost treatment?
- Digital therapy aims to tame the fear that haunts cancer survivors
- Can a vaccine train the immune system to hunt down hidden breast cancer cells?
- Could a common cholesterol drug boost breast cancer treatment?
- Gene test could guide breast cancer treatment to boost survival